S'abonner

Enhanced osteoclastogenesis in patients with MSMD due to impaired response to IFN-? - 05/01/22

Doi : 10.1016/j.jaci.2021.05.018 
Miyuki Tsumura, PhD a, , Mizuka Miki, MD a, b, , , Yoko Mizoguchi, MD, PhD a, Osamu Hirata, MD, PhD a, c, , Shiho Nishimura, MD, PhD a, d, , Moe Tamaura, MD, PhD a, e, , Reiko Kagawa, MD, PhD a, Seiichi Hayakawa, MD, PhD a, Masao Kobayashi, MD, PhD a, f, , §, Satoshi Okada, MD, PhD a, , §
a Department of Pediatrics, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan 
b Department of Pediatrics, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Japan 
c Hidamari Children Clinic, Hiroshima, Japan 
d Department of Pediatrics, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan 
e Department of Pediatrics, Hiroshima-Nishi Medical Center, Hiroshima, Japan 
f Japanese Red Cross, Chugoku-Shikoku Block Blood Center, Hiroshima, Japan 

Corresponding author: Satoshi Okada, MD, PhD, Department of Pediatrics, Hiroshima University Graduate School of Biomedical and Health Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8551, Japan.Department of PediatricsHiroshima University Graduate School of Biomedical and Health Sciences1-2-3 KasumiMinami-kuHiroshima734-8551Japan

Abstract

Background

Patients with Mendelian susceptibility to mycobacterial disease (MSMD) experience recurrent and/or persistent infectious diseases associated with poorly virulent mycobacteria. Multifocal osteomyelitis is among the representative manifestations of MSMD. The frequency of multifocal osteomyelitis is especially high in patients with MSMD etiologies that impair cellular response to IFN-γ, such as IFN-γR1, IFN-γR2, or STAT1 deficiency.

Objectives

This study sought to characterize the mechanism underlying multifocal osteomyelitis in MSMD.

Methods

GM colonies prepared from bone marrow mononuclear cells from patients with autosomal dominant (AD) IFN-γR1 deficiency, AD STAT1 deficiency, or STAT1 gain of function (GOF) and from healthy controls were differentiated into osteoclasts in the presence or absence of IFN-γ. The inhibitory effect of IFN-γ on osteoclastogenesis was investigated by quantitative PCR, immunoblotting, tartrate-resistant acid phosphatase staining, and pit formation assays.

Results

Increased osteoclast numbers were identified by examining the histopathology of osteomyelitis in patients with AD IFN-γR1 deficiency or AD STAT1 deficiency. In the presence of receptor activator of nuclear factor kappa-B ligand and M-CSF, GM colonies from patients with AD IFN-γR1 deficiency, AD STAT1 deficiency, or STAT1 GOF differentiated into osteoclasts, similar to GM colonies from healthy volunteers. IFN-γ concentration-dependent inhibition of osteoclast formation was impaired in GM colonies from patients with AD IFN-γR1 deficiency or AD STAT1 deficiency, whereas it was enhanced in GM colonies from patients with STAT1 GOF.

Conclusions

Osteoclast differentiation is increased in AD IFN-γR1 deficiency and AD STAT1 deficiency due to an impaired response to IFN-γ, leading to excessive osteoclast proliferation and, by inference, increased bone resorption in infected foci, which may underlie multifocal osteomyelitis.

Le texte complet de cet article est disponible en PDF.

Key words : Mendelian susceptibility to mycobacterial diseases, MSMD, STAT1, IFN-γR1, mycobacteria, osteomyelitis, osteoclastogenesis

Abbreviations used : AD, AR, BM-MNCs, CNO, GOF, IRF, MSMD, NFATc1, RANKL, TRAP


Plan


 This study was supported in part by Grants in Aid for Scientific Research from the Japan Society for the Promotion of Science (grants 15K21189, 17K10112, and 20K08158 to M.T.; 22591161 to M.K.; 16H05355 and 19H03620 to S.O.) and was supported in part by the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (grants JP16ek0109179, JP19ek0109209, and JP20ek0109480 to S.O.).
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2021  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 149 - N° 1

P. 252 - janvier 2022 Retour au numéro
Article précédent Article précédent
  • Targeting androgen signaling in ILC2s protects from IL-33–driven lung inflammation, independently of KLRG1
  • Eve Blanquart, Audrey Mandonnet, Marion Mars, Claire Cenac, Nina Anesi, Pascale Mercier, Christophe Audouard, Stephane Roga, Gilberto Serrano de Almeida, Charlotte L. Bevan, Jean-Philippe Girard, Lucette Pelletier, Sophie Laffont, Jean-Charles Guéry
| Article suivant Article suivant
  • Oral anaphylaxis to peanut in a mouse model is associated with gut permeability but not with Tlr4 or Dock8 mutations
  • Jake A. Gertie, Biyan Zhang, Elise G. Liu, Laura R. Hoyt, Xiangyun Yin, Lan Xu, Lauren L. Long, Arielle Soldatenko, Uthaman Gowthaman, Adam Williams, Stephanie C. Eisenbarth

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.